Is CASI Pharmaceuticals Inc halal to invest in?

According to Musaffa's Shariah screening methodology, CASI Pharmaceuticals Inc (CASI) is currently classified as NOT HALAL as of December 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is CASI Pharmaceuticals Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes CASI Pharmaceuticals Inc using these criteria to determine its compliance status.

Can Muslims buy shares of CASI Pharmaceuticals Inc?

Muslim investors may consider investing in CASI Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is CASI Pharmaceuticals Inc classified as NOT HALAL?

Musaffa determines the Shariah status of CASI Pharmaceuticals Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for CASI Pharmaceuticals Inc updated?

The Shariah compliance status of CASI Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like CASI Pharmaceuticals Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of CASI Pharmaceuticals Inc?

You can check the latest Shariah compliance status of CASI Pharmaceuticals Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

CASI Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: December 03, 2025

Report Source: 2025 3rd Quarter Report

Analyst's Ratings for CASI Pharmaceuticals Inc (CASI)

Based on 7 analysts giving stock ratings to CASI Pharmaceuticals Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

CASI Pharmaceuticals Inc. Stock Analysis CASI

United States Health Care Nano Cap Report: Q3, 2025

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The firm mainly conducts its business in the domestic market.

Key Statistics of CASI Pharmaceuticals Inc (CASI)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.21$0.37

Today's Open

$0.34

Volume

3821.00

P/E Ratio (TTM)

52 Week Range

$0.21$3.09

Market Cap

15.80M

Avg. Volume

5180.00

Dividend Yield

Financial Metrics & Statements of CASI Pharmaceuticals Inc (CASI)

FAQ's for CASI Pharmaceuticals Inc (CASI)

According to Musaffa’s Shariah screening methodology, CASI Pharmaceuticals Inc (CASI) is currently classified as NOT HALAL as of December 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.